-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Lid5zMapt4tBEOzLGhqzI8JZYoKbrBOR8K4NU+qMJ8kv3Zvt8O4tSIndJ3tR4ANP
 4m2w6vEOR8MAe1iC/jhDPw==

<SEC-DOCUMENT>0001144204-06-027429.txt : 20060706
<SEC-HEADER>0001144204-06-027429.hdr.sgml : 20060706
<ACCEPTANCE-DATETIME>20060705205833
ACCESSION NUMBER:		0001144204-06-027429
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20060705
FILED AS OF DATE:		20060706
DATE AS OF CHANGE:		20060705

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			pSivida LTD
		CENTRAL INDEX KEY:			0001314102
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51122
		FILM NUMBER:		06946157

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12 BGC CENTRE
		STREET 2:		28 THE ESPLANADE
		CITY:			PERTH
		STATE:			C3
		ZIP:			6000
		BUSINESS PHONE:		61 8 9226 5099

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12 BGC CENTRE
		STREET 2:		28 THE ESPLANADE
		CITY:			PERTH
		STATE:			C3
		ZIP:			6000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v046924_6k.htm
<TEXT>
<html>
  <head>
    <title>
      Unassociated Document
</title><!-- Licensed to: vf-->
<!-- Document Created using EDGARizer HTML 3.0.4.0 -->
<!-- Copyright 2006 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff"><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><a name="return"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      AND EXCHANGE COMMISSION<br></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
      D.C. 20549</strong></font></a></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>FORM
      6-K</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">REPORT
      OF
      FOREIGN ISSUER<br></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to Rule 13a-16 or 15d-16 of<br></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
      Securities Exchange Act of 1934</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>For
      the month of July 2006</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Commission
      File Number 000-5112</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>pSivida
      Limited<br></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
      of registrant&#8217;s name into English) </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level
      12
      BGC Centre<br></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">28
      The
      Esplanade<br></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Perth
      WA
      6000<br></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
      of principal executive offices)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Indicate
      by check mark whether the registrant files or will file annual reports under
      cover Form&#160;20-F or Form&#160;40-F). </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      20-F
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form
      40-F </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(1):</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(7):</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether the registrant by furnishing the information contained
      in
      this Form is also thereby furnishing the information to the Commission pursuant
      to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      "Yes"
      is marked, indicate below the file number assigned to the registrant in
      connection with Rule&#160;12g3-2(b): 82- ___. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURE
      </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to the requirements of the Securities Exchange Act of 1934, the registrant,
      pSivida Limited, has duly caused this report to be signed on its behalf by
      the
      undersigned, thereunto duly authorized. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
      <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

          <tr valign="top" bgcolor="#ffffff">
            <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">Date:&#160;July
              5,
              2006</font></td>
            <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">pSivida
              Limited</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td>&#160;</td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">By:&#160;&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">/s/&#160;Aaron
              Finlay</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="FONT-FAMILY: " size="1">&#160;</font></td>
            <td align="left">
              <hr style="COLOR: black" align="left" noshade size="2" width="80%">
            </td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Aaron
                Finlay</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Company
                Secretary</em></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="1">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>EXHIBIT
      INDEX</u></em></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>EXHIBIT
                99.1:</strong></font></div>
            </td>
            <td align="left" valign="top" width="62%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>New
                Discovery: BioSilicon</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup><strong>TM</strong></sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>
                Demonstrates Adjuvant Properties</strong></font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">&#160;</td>
            <td align="left" valign="top" width="62%">&#160;</td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="1">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v046924_ex99-1.htm
<TEXT>
<html>
  <head>
    <title>
      Unassociated Document
</title><!-- Licensed to: vf-->
<!-- Document Created using EDGARizer HTML 3.0.4.0 -->
<!-- Copyright 2006 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff">
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div align="center">
      <table bgcolor="white" cellpadding="0" cellspacing="0" width="100%">

          <tr bgcolor="white">
            <td width="50%">&#160;</td>
            <td width="50%">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><img src="psivida_logo.jpg"></div>
            </td>
          </tr>
          <tr bgcolor="white">
            <td width="50%"><strong><font size="2">ASX/MEDIA RELEASE</font></strong></td>
            <td width="50%">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><strong><font size="2">5
                July
                2006</font></strong></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman"><strong>New
      Discovery:
      BioSilicon</strong><sup><strong>TM</strong></sup><strong>&#160;</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman"><strong>Demonstrates
      Adjuvant Properties</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 16pt; FONT-FAMILY: Times New Roman"><strong>Potential
      to be exploited in delivery of vaccines</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
      <div>
        <hr style="COLOR: black" align="center" noshade size="1" width="100%">
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Boston,
      MA. and Perth, Australia - Global bio-nanotech company pSivida Limited (ASX:PSD,
      NASDAQ:PSDV, Xetra:PSI) is pleased to announce that its novel drug delivery
      platform, BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      has
      demonstrated the capability to act as an adjuvant when delivered with an
      antigen. A patent application has been filed in the U.K. which covers the
      application of BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      as an
      adjuvant.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <table cellpadding="0" cellspacing="0" id="list" width="100%">

        <tr valign="top" style="line-height: 1.25;">
          <td align="right" style="width: 27pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
          <td>
            <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
              vaccine is any substance bearing antigens (any substance capable of
              eliciting an immune response) on its surface that causes activation
              of a
              human&#8217;s or animals' immune system without causing actual
              disease.</font></div>
          </td>
        </tr>

    </table>
    <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <table cellpadding="0" cellspacing="0" id="list" width="100%">

        <tr valign="top" style="line-height: 1.25;">
          <td align="right" style="width: 27pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
          <td>
            <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">An
              adjuvant is any substance that is capable of enhancing a host response
              towards an active agent and is often used in conjunction with antigens
              to
              enhance the immune response of humans and
              animals.</font></div>
          </td>
        </tr>

    </table>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Recent
      in
      vivo pre-clinical data demonstrate that BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      alone
      does not stimulate the immune system. This finding is critical since it confirms
      the biocompatible attribute of this novel biodegradable biomaterial. The
      controlled study also demonstrated that certain forms of BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
      delivered in specific combinations with a specific antigen, showed an adjuvant
      activity equivalent to the well established and widely used adjuvant, alum
      (aluminium salts). </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-antigen
      combinations resulted in an enhanced immune response based on </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>in
      vivo</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      antibody
      responses. This finding opens up the potential for exploiting
      BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      not only
      for the delivery of vaccines, but also for enhancing the immune response to
      those vaccines. The global market for vaccines is estimated at $8
      billion.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;This
      finding indicates the potential utility of BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      in the
      vaccine delivery market,&#8221; said Mr Gavin Rezos, CEO of pSivida Limited. &#8220;The
      discovery of the adjuvant properties of BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      presents
      an exciting new development and widens the potential market for this novel
      biodegradable biomaterial&#8221;.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>-ENDS-</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="1">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br>&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="left" valign="top" width="26%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>pSivida
                Limited</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Brian
                Leedman</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Investor
                Relations</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                Limited</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                + 61 8 9226 5099</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">brianl@psivida.com</font></div>
            </td>
            <td align="left" valign="top" width="26%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>US
                Public Relations</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Beverly
                Jedynak</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">President</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Martin
                E. Janis &amp; Company, Inc</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                +1 (312) 943 1100 ext. 12</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">bjedynak@janispr.com</font></div>
            </td>
            <td align="left" valign="top" width="26%">&#160;</td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>NOTES
      TO EDITORS: </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      is a global bio-nanotech company committed to the biomedical sector and the
      development of drug delivery products. Retisert&#8482; is FDA approved for the
      treatment of uveitis. Vitrasert&#174; is FDA approved for the treatment of
      AIDS-related CMV Retinitis. Bausch &amp; Lomb own the trademarks Vitrasert&#174; and
      Retisert&#8482;. pSivida has licensed the technologies underlying both of these
      products to Bausch &amp; Lomb. The technology underlying Medidur&#8482;, a treatment
      for diabetic macular edema, is licensed to Alimera Sciences and is in Phase
      III
      clinical trials.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      owns the rights to develop and commercialise a modified form of silicon
      (porosified or nano-structured silicon) known as BioSilicon&#8482;, which has
      applications in drug delivery, wound healing, orthopaedics, and tissue
      engineering. pSivida&#8217;s subsidiary, AION Diagnostics Limited is developing
      diagnostic products and the subsidiary pSiNutria is developing food technology
      products both using BioSilicon&#8482;. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida&#8217;s
      intellectual property portfolio consists of 70 patent families, 74 granted
      patents and over 290 patent applications.</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      pSivida
      conducts its operations from offices and facilities near Boston in the United
      States, Malvern in the United Kingdom, Perth in Australia and Singapore.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      is listed on NASDAQ (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSDV</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">),
      the
      Australian Stock Exchange (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSD</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">)
      and on
      the Frankfurt Stock Exchange on the XETRA system (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>German</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Symbol:
      PSI. Securities Code (WKN) 358705</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">).
      pSivida is a founding member of the NASDAQ Health Care Index and the Merrill
      Lynch Nanotechnology Index.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Company's largest shareholder and a strategic partner is QinetiQ, a leading
      international defence, security and technology company, formed in 2001 from
      the
      UK Government's Defence Evaluation &amp; Research Agency (DERA). QinetiQ (QQ.)
      was instrumental in discovering BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      and
      pSivida enjoys a strong relationship with, including access to its cutting
      edge
      research and development facilities.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      more
      information, visit </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>www.psivida.com</u></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
      document contains forward-looking statements that involve risks and
      uncertainties. The statements reference potential products, applications and
      regulatory approvals. Although we believe that the expectations reflected in
      such forward-looking statements are reasonable at this time, we can give no
      assurance that such expectations will prove to be correct. Given these
      uncertainties, readers are cautioned not to place undue reliance on such
      forward-looking statements. Actual results could differ materially from those
      anticipated in these forward-looking statements due to many important factors
      including: BioSilicon&#8217;s&#8482; inability to deliver vaccines or its unsuitability to
      enhance the immune response to vaccines; our failure to achieve regulatory
      approvals for the use of BioSilicon&#8482; as an adjuvant; unfavourable changes in the
      market for vaccines or adjuvants; our inability to recreate the results of
      our
      pre-clinical data concerning BioSilicon&#8217;s&#8482; adjuvant properties; our inability to
      develop proposed products, including without limitation, in the drug delivery,
      wound healing, orthopaedics, and tissue engineering, diagnostics and food
      technology fields; failure of our evaluation agreements to result in license
      agreements; failure to develop applications for BioSilicon&#8482; due to regulatory,
      scientific or other issues;failure to complete negotiations for new centers
      for
      the BrachySil&#8482; phase&#160;IIb clinical trial for inoperable primary liver
      cancer; failure of our discussions with the FDA for BrachySil&#8482; to continue or to
      lead to FDA approval; failure of the BrachySil&#8482; phase&#160;IIb clinical trial
      for inoperable primary liver cancer to determine the optimal dose, provide
      key
      safety data or support future pivotal efficacy trials or product registration
      or
      approval; failure of the BrachySil&#8482; primary liver programme that is in
      phase&#160;IIb clinical trials to&#160;provide a valuable platform for the
      development and commercialisation of BrachySil&#8482; for pancreatic cancer and other
      indications; failure to commence phase&#160;IIa BrachySil</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      trials
      for the treatment of pancreatic cancer; failure of the findings&#160;of the
      pancreatic cancer phase&#160;IIa trial to provide a platform for further
      multicentre efficacy and safety trials; failure of there to be
      optimisation&#160;and standardisation between our two&#160; pancreatic
      cancer&#160;study&#160;centres; failure of the results of the Retisert&#8482; for DME
      trial to be a good indicator of the results of pSivida&#8217;s ongoing phase&#160;III
      Medidur&#8482; for DME trial; failure of </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
      Medidur</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8482;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      trials
      in DME to show a very similar improvement in visual acuity and diabetic
      retinopathy severity score as Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8482;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      for
      DME</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">;
      failure
      of Medidur&#8482; to release fluocinolone acetonide at the same rate as Retisert&#8482;; our
      inability to recruit patients for the phase&#160;III Medidur&#8482; for DME
      trial;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Other
      reasons are contained in cautionary statements in the Annual Report on Form
      20-F
      filed with the U.S. Securities and Exchange Commission, including, without
      limitation, under Item 3.D, "Risk Factors" therein. We do not undertake to
      update any oral or written forward-looking statements that may be made by or
      on
      behalf of pSivida.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="1">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>psivida_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 psivida_logo.jpg
M_]C_X``02D9)1@`!`@$`2`!(``#_X0SW17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````;````<@$R``(````4````C8=I``0````!````I````-````!(````
M`0```$@````!061O8F4@4&AO=&]S:&]P($-3(%=I;F1O=W,`,C`P-CHP-#HP
M,R`P,3HP,3HS-0```````Z`!``,````!``$``*`"``0````!````M*`#``0`
M```!````-0`````````&`0,``P````$`!@```1H`!0````$```$>`1L`!0``
M``$```$F`2@``P````$``@```@$`!`````$```$N`@(`!`````$```O!````
M`````$@````!````2`````'_V/_@`!!*1DE&``$"`0!(`$@``/_M``Q!9&]B
M95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,
M#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`+P"@`P$B``(1`0,1`?_=``0`
M"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$`
M`````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$%
M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D
M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B
M$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D
M154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=7
M9W>'EZ>WQ__:``P#`0`"$0,1`#\`]52253/.36P6TVBMK.6.#8)/T=S[',V)
MF7)[<#/A,N'4B-<5?X7"D"S3;25/%S+<S$+ZMK+VG:X.ES9']4CVN:J#^K9[
M,@T$5%X?LF'1,[?WE6R_$<&.&/(>(PR_)*,;L_N_WDB!-CLZ/4.IX'3,<Y.?
M>VBJ=H+N7./%=;&R^VQW^CK;O68W(^L?5CNQ:QT7!/%N0P69;QIJS$)]##;_
M`.&?6N_[K5HU^#AXESNLY=++^I`>G5:2]VT'39CLN?8S&_X7T/3WHE>3U$T.
MO86WW.&RK'`:&"P_GOOK=8YM-?\`A?S_`/KGIL4OWF'NQQ",CDD.,CT_JX]\
MGJ6&)())J(_=WDT.G?;\;ZT6=/9GWY^(S$];+&1Z;C5<]^W%;6^BNGT_6J9>
M_P!']Q=$J/2>ELZ=0\.L.1E9#S=EY3A#K;3HY^T?S=;&M]*BG_`TL96KRG1$
M4%))*CG]39AN;6UOJ6N$[9@`>94>;-CPP.3)+A@.J\`DT&\DLNGK)]8595)H
MF/<9TGC<UX;[?Y2N9MF373NQ6"RR0-I\._=JCQ\YAR8YY,9,QC^>(C+W(_\`
M4_F48D&CU;"2%C.M?0QUS=EI'O;X'\453QEQ1$A8X@#KH=4*26=U_)ZKB],L
MNZ10,K-:Y@92X2""X"S\^KZ+/Y:GT3(ZCD]+HOZI2,;->#ZU($!I#G!OYUGY
MFW\]%'%ZN'7:_!O)*KU3,.!TW*S@SU#C4ON%<[=VQI?MW>[;NVJA]5NONZ_T
MY^:Z@8Q9<ZK8'[YVACMV[:S_`$B2#,"0C?J(MV4DDDES_]#U5!RP?L[XT($R
M#'&OTMU?_5HRP^M]4R[,IG0>CN#>I7MWWY)&YN)0?:<FQOY^19]##Q_\)9^D
ML_15ILX\<91_>!C_`(R#*M4&[JCV9&-TEU;,K)M:'9-A#A140[U,QC-S_M5S
M/H54^I_/?SWZ-0L;MZCLDN+;6M+G<D@M;O=$>Y_TEK6=(;86/.1=ZK`!ZA=K
M/=W'LW?\'[%CV5N&<:M[G.%H;ZA^E,@;_P"LN=Y^&;#AP89P'##,3CR"0_6<
M4C/Y?T?F9H4297N-NSJ];>TLHJD2ZP.@F-!W[?O*WA2:`XF=Q)!G=I_6WW?]
M6J]/2JFVFYV1;;8-"[?!_JN<WW_]):"U^7P93S&3F,L?;,P(1QWQ^F/64EA(
MH`:J7!9_4_K"_P"OMW2>GYQI98T,K;:`^JN<=MUMS:=/4M9M>^ECW^GZW\Y^
MC7>KSRVVJG_&MOM>VMDM;N<0!N=B;&-EWYSWG8Q7AU\FMS!(&.C5Y(@^27I'
M4.N]'^N8Z'U#.LZACY&F^W7Z5;KZ;JV_X%VZMU-E6[TETO5J+Z<MN=6W>QNT
MGN&EO[_\ARY;-L9D?XT<84D/](L8^-8<RFZRQO\`8:_W+LLCJOV?,&/97MKT
M)MG\TCZ0;'YK_I*E\3CAEAB,TSBN4>#(!?!E_0E+^JOY4FY@>H1E(#^ZPIR>
MG=2<P7U@7-G:QW!GG:?HO1>KVVTX>^IQ8[<T2/!9G5FX;;6/Q'-WF2X5G0$1
ML<-OT7K0ZSN/3AN^EN;/Q5$<Q,X>=A+@.;%$7S&'T^[<?09&/Z<6Q0N)Z'H7
M*^L]W4V_5/[;A9-E.3C[+7V5D;G,G9:UWM=[=K_4_P"MK,SOK1F#Z@8N=7>Y
MF?>YF,;P1O#ZW.]:SCZ5E5#O^W5U5.+7F=%^R6_S>12ZI_P>"QW_`%2\FQ*L
MO+?A_5FUI;MSG"SQ#G;<?)]O_`LINL6MRNN#$3J>"!)/]UI<U*4)FB?U@,!_
M?M[;J&7UC!_Q?U9;\NW]H/%5CLB1O'JV-?L^C^;59Z7T5;Z9UK+H^H8ZO?8<
MC+KHM>'V:[GA]C*O4V[/;NV*7^,$`?57(`$`/I``_P",8LW'8Y_^*UP:)(QK
M''X-M>]W_1:INGU43*.20!/IQ?\`.<KI[?K3G_5SJ76+.JFVAU=U=N)>W>U]
M88?M#ZRW;]EL;[OL_I,V?Z1;/^+JRRGZK9=M59OLKR+G,I:0"]PKJ<VMKG>W
M<_Z*I?5_+QF_XNNI,?:QCF-R:W!Q`.ZQI]%FOYUN[]'^^B_4OJ(Z7]2NH=0+
M/4./?:]K/%VRD,:?Y._Z21Z^;'CH2QRL_P`W*1-VUWX/U_S,7,ZKG9]G378S
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MWRQSB(CP"4#Q1EDC[G"?ZL/E_P`=?$G]+0?NQ_[J3+'=CNJ`QBPU-T&P@@?Y
MJ*HU^GM_1QM_DQ$_)25F/%0XJXNM;)\E+SC,Q<3._P`:%F%F5MNHO;MLJ?J"
M/LF[_HQN:O1T#]1^U?X+[5_9]3C_`+<_FTX&F/+CX^'^K(3_`,5RNB?4[HG1
M,IV7AL>Z\@M8ZUV_8T_2;3QMW?O_`,XM7)P\?*:&W-G;]%PT(^!1TDR<(Y(F
M,XB<3O&0L+XQ$!41P^32Q^DX=#Q8UI>YIEI>9@^,*QDXU637Z5H);(.AC4(J
M2CARV&$#CCCC&$OFB!I+^\NLW=L*:F4U-J9]!@@3JLJCZJ=&Q^LNZU56X9KG
M/L)WN+-U@V6.%?T?=[O\];"2EB!$",10`H`=EIB#1(NC8:?5>EXG5L)^#F!S
MJ+"TN#7%IEI#V^YO\IJ6#TK"P>FLZ92S=B,:YGIV'?+7ESGM?O\`I[MZN)(J
MX1=UK57X/-8_^+SZLX][[A2^PN:YM;+'ES:P\%GZ&?SFM=^C?9ZGIK2Z=]7.
ME=.Z;=TNBLNP\@O-M=CB_=ZC178-SO=]!JTTDK*T8X#:(#S.+_B[^K./<ZXT
MOO)!:QMSR]K-P+?8/;[FM=[/4WK4Z)T#IW0Z;*<`/:RYP>_>\O.X`,_._JK2
M22M4<<(ZB(%/_]G_[1&R4&AO=&]S:&]P(#,N,``X0DE-!"4``````!``````
M````````````````.$))30/M```````0`$@````!``$`2`````$``3A"24T$
M)@``````#@`````````````_@```.$))300-```````$````>#A"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$`````````@`!.$))300"```````$`````#A"24T$"```````
M$`````$```)````"0``````X0DE-!!X```````0`````.$))300:``````-)
M````!@``````````````-0```+0````*`%4`;@!T`&D`=`!L`&4`9``M`#$`
M```!``````````````````````````$``````````````+0````U````````
M``````````````$`````````````````````````$`````$```````!N=6QL
M`````@````9B;W5N9'-/8FIC`````0```````%)C=#$````$`````%1O<"!L
M;VYG``````````!,969T;&]N9P``````````0G1O;6QO;F<````U`````%)G
M:'1L;VYG````M`````9S;&EC97-6;$QS`````4]B:F,````!```````%<VQI
M8V4````2````!W-L:6-E241L;VYG``````````=G<F]U<$E$;&]N9P``````
M```&;W)I9VEN96YU;0````Q%4VQI8V5/<FEG:6X````-875T;T=E;F5R871E
M9`````!4>7!E96YU;0````I%4VQI8V54>7!E`````$EM9R`````&8F]U;F1S
M3V)J8P````$```````!28W0Q````!`````!4;W`@;&]N9P``````````3&5F
M=&QO;F<``````````$)T;VUL;VYG````-0````!29VAT;&]N9P```+0````#
M=7)L5$585`````$```````!N=6QL5$585`````$```````!-<V=E5$585```
M``$```````9A;'1486=415A4`````0``````#F-E;&Q497AT27-(5$U,8F]O
M;`$````(8V5L;%1E>'1415A4`````0``````"6AO<GI!;&EG;F5N=6T````/
M15-L:6-E2&]R>D%L:6=N````!V1E9F%U;'0````)=F5R=$%L:6=N96YU;0``
M``]%4VQI8V5697)T06QI9VX````'9&5F875L=`````MB9T-O;&]R5'EP965N
M=6T````115-L:6-E0D=#;VQO<E1Y<&4`````3F]N90````ET;W!/=71S971L
M;VYG``````````IL969T3W5T<V5T;&]N9P`````````,8F]T=&]M3W5T<V5T
M;&]N9P`````````+<FEG:'1/=71S971L;VYG```````X0DE-!"@```````P`
M```!/_`````````X0DE-!!0```````0````".$))300,``````O=`````0``
M`*`````O```!X```6"````O!`!@``?_8_^``$$I&248``0(!`$@`2```_^T`
M#$%D;V)E7T--``'_[@`.061O8F4`9(`````!_]L`A``,"`@("0@,"0D,$0L*
M"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,`0T+"PT.#1`.#A`4#@X.%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"``O`*`#`2(``A$!`Q$!
M_]T`!``*_\0!/P```04!`0$!`0$``````````P`!`@0%!@<("0H+`0`!!0$!
M`0$!`0`````````!``(#!`4&!P@)"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#
M!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#
M)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6
MIK;&UN;V-T=79W>'EZ>WQ]?G]Q$``@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($
M05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$
MDU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]B<W1U=G=X>7I[?'_]H`#`,!``(1`Q$`/P#U5))5,\Y-;!;3:*VLY8X-@D_1
MW/L<S8F9<GMP,^$RX=2(UQ5_A<*0+--M)4\7,MS,0OJVLO:=K@Z7-D?U2/:Y
MJH/ZMGLR#0147A^R8=$SM_>5;+\1P8X8\AXC#+\DHQNS^[_>2($V.SH]0ZG@
M=,QSDY][:*IV@NY<X\5UL;+[;'?Z.MN]9C<CZQ]6.[%K'1<$\6Y#!9EO&FK,
M0GT,-O\`X9]:[_NM6C7X.'B7.ZSETLOZD!Z=5I+W;0=-F.RY]C,;_A?0]/>B
M5Y/430Z]A;?<X;*L<!H8+#^>^^MUCFTU_P"%_/\`^N>FQ2_>8>['$(R.20XR
M/3^KCWR>I88D@DFHC]W>30Z=]OQOK19T]F??GXC,3ULL9'IN-5SW[<5M;Z*Z
M?3]:IE[_`$?W%T2H])Z6SIU#PZPY&5D/-V7E.$.MM.CG[1_-UL:WTJ*?\#2Q
ME:O*=$104DDJ.?U-F&YM;6^I:X3MF`!YE1YLV/#`Y,DN&`ZKP"30;R2RZ>LG
MUA5E4FB8]QG2>-S7AOM_E*YFV9-=.[%8++)`VGP[]VJ/'SF')CGDQDS&/YXB
M,O<C_P!3^91B0:/5L)(6,ZU]#'7-V6D>]O@?Q15/&7%$2%CB`.NAU0I)9W7\
MGJN+TRR[I%`RLUKF!E+A((+@+/SZOHL_EJ?1,CJ.3TNB_JE(QLUX/K4@0&D.
M<&_G6?F;?ST4<7JX==K\&\DJO5,PX'3<K.#/4.-2^X5SMW;&E^W=[MN[:J'U
M6Z^[K_3GYKJ!C%ESJM@?OG:&.W;MK/\`2)(,P)"-^HBW922227/_T/54'+!^
MSOC0@3(,<:_2W5_]6C+#ZWU3+LRF=!Z.X-ZE>W??DD;FXE!]IR;&_GY%GT,/
M'_PEGZ2S]%6FSCQQE']X&/\`C(,JU0;NJ/9D8W275LRLFUH=DV$.%%1#O4S&
M,W/^U7,^A53ZG\]_/?HU"QNWJ.R2XMM:TN=R2"UN]T1[G_26M9TAMA8\Y%WJ
ML`'J%VL]W<>S=_P?L6/96X9QJWN<X6AOJ'Z4R!O_`*RYWGX9L.'!AG`<,,Q.
M/()#]9Q2,_E_1^9FA1)E>XV[.KUM[2RBJ1+K`Z"8T'?M^\K>%)H#B9W$D&=V
MG];?=_U:KT]*J;:;G9%MM@T+M\'^JYS??_TEH+7Y?!E/,9.8RQ]LS`A''?'Z
M8]926$B@!JI<%G]3^L+_`*^W=)Z?G&EEC0RMMH#ZJYQVW6W-IT]2UFU[Z6/?
MZ?K?SGZ-=ZO/+;:J?\:V^U[:V2UNYQ`&YV)L8V7?G/>=C%>'7R:W,$@8Z-7D
MB#Y)>D=0Z[T?ZYCH?4,ZSJ&/D:;[=?I5NOINK;_@7;JW4V5;O272]6HOIRVY
MU;=[&[2>X:6_O_R'+ELVQF1_C1QA20_TBQCXUAS*;K+&_P!AK_<NRR.J_9\P
M8]E>VO0FV?S2/I!L?FO^DJ7Q..&6&(S3.*Y1X,@%\&7]"4OZJ_E2;F!ZA&4@
M/[K"G)Z=U)S!?6!<V=K'<&>=I^B]%ZO;;3A[ZG%CMS1(\%F=6;AMM8_$<W>9
M+A6=`1&QPV_1>M#K.X].&[Z6YL_%41S$SAYV$N`YL41?,8?3[MQ]!D8_IQ;%
M"XGH>A<KZSW=3;]4_MN%DV4Y./LM?961N<R=EK7>UWMVO]3_`*VLS.^M&8/J
M!BYU=[F9][F8QO!&\/K<[UK./I654._[=754XM>9T7[);_-Y%+JG_!X+'?\`
M5+R;$JR\M^']6;6ENW.<+/$.=MQ\GV_\"RFZQ:W*ZX,1.IX($D_W6ES4I0F:
M)_6`P']^WMNH9?6,'_%_5EOR[?V@\56.R)&\>K8U^SZ/YM5GI?15OIG6LNCZ
MACJ]]AR,NNBUX?9KN>'V,J]3;L]N[8I?XP0!]5<@`0`^D`#_`(QBS<=CG_XK
M7!HDC&L<?@VU[W?]%JFZ?51,HY)`$^G%_P`YRNGM^M.?]7.I=8LZJ;:'5W5V
MXE[=[7UAA^T/K+=OV6QON^S^DS9_I%L_XNK+*?JMEVU5F^RO(N<REI`+W"NI
MS:VN=[=S_HJE]7\O&;_BZZDQ]K&.8W)K<'$`[K&GT6:_G6[OT?[Z+]2^HCI?
MU*ZAU`L]0X]]KVL\7;*0QI_D[_I)'KYL>.A+'*S_`#<I$W;7?@_7_,Q<SJN=
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MYXVVW8?1Z3R:`[*O^3K_`$L9G^9:BQD^K8FMNSK=1ZMT_IE3;,ZYM7J';4S5
MUECI`]/'HKW77V>[Z%3%SCGVY66;\H.PJ++`X8H=^L$$_2S+JY;A^W_M+C.^
MT_Z6^K^;6GTKIGU?Z=U%U;<AN7UM[9MMR;FVYA9'[KCOIIV_F4UU5+5'V.-/
M3CRVJIS?+'.(B/`)0/%&62/N<)_JP^7_`!U\2?TM!^['_NI,L=V.ZH#&+#4W
M0;""!_FHJC7Z>W]'&W^3$3\E)68\5#BKBZULGR4O.,S%Q,[_`!H68696VZB]
MNVRI^H(^R;O^C&YJ]'0/U'[5_@OM7]GU./\`MS^;3@:8\N/CX?ZLA/\`Q7*Z
M)]3NB=$RG9>&Q[KR"UCK7;]C3])M/&W=^_\`SBU<G#Q\IH;<V=OT7#0CX%'2
M3)PCDB8SB)Q.\9"POC$0%1'#Y-+'Z3AT/%C6E[FF6EYF#XPK&3C59-?I6@EL
M@Z&-0BI*.'+880....,82^:(&DO[RZS=VPIJ934VIGT&"!.JRJ/JIT;'ZR[K
M55;AFN<^PG>XLW6#98X5_1]WN_SUL)*6($0(Q%`"@!V6F(-$BZ-AI]5Z7B=6
MPGX.8'.HL+2X-<6F6D/;[F_RFI8/2L+!Z:SIE+-V(QKF>G8=\M>7.>U^_P"G
MNWJXDBKA%W6M5?@\UC_XO/JSCWON%+["YKFULL>7-K#P6?H9_.:UWZ-]GJ>F
MM+IWU<Z5T[IMW2Z*R[#R"\VUV.+]WJ-%=@W.]WT&K322LK1C@-H@/,XO^+OZ
MLX]SKC2^\D%K&W/+VLW`M]@]ON:UWL]3>M3HG0.G=#ILIP`]K+G![][R\[@`
MS\[^JM))*U1QPCJ(@4__V0`X0DE-!"$``````%,````!`0````\`00!D`&\`
M8@!E`"``4`!H`&\`=`!O`',`:`!O`'`````2`$$`9`!O`&(`90`@`%``:`!O
M`'0`;P!S`&@`;P!P`"``0P!3`````0`X0DE-!`8```````<`!`````$!`/_A
M%_EH='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O`#P_>'!A8VME="!B96=I
M;CTG[[N_)R!I9#TG5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED)S\^"CQX.GAM
M<&UE=&$@>&UL;G,Z>#TG861O8F4Z;G,Z;65T82\G('@Z>&UP=&L])UA-4"!T
M;V]L:VET(#,N,"TR."P@9G)A;65W;W)K(#$N-B<^"CQR9&8Z4D1&('AM;&YS
M.G)D9CTG:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X
M+6YS(R<@>&UL;G,Z:5@])VAT='`Z+R]N<RYA9&]B92YC;VTO:5@O,2XP+R<^
M"@H@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70])W5U:60Z869D-V5E-6$M
M8S)C92TQ,61A+6$W-6,M.#0Y9#@Q-6%C,V-C)PH@('AM;&YS.F5X:68])VAT
M='`Z+R]N<RYA9&]B92YC;VTO97AI9B\Q+C`O)SX*("`\97AI9CI#;VQO<E-P
M86-E/C$\+V5X:68Z0V]L;W)3<&%C93X*("`\97AI9CI0:7AE;%A$:6UE;G-I
M;VX^,3@P/"]E>&EF.E!I>&5L6$1I;65N<VEO;CX*("`\97AI9CI0:7AE;%E$
M:6UE;G-I;VX^-3,\+V5X:68Z4&EX96Q91&EM96YS:6]N/@H@/"]R9&8Z1&5S
M8W)I<'1I;VX^"@H@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70])W5U:60Z
M869D-V5E-6$M8S)C92TQ,61A+6$W-6,M.#0Y9#@Q-6%C,V-C)PH@('AM;&YS
M.G!D9CTG:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R<^"B`\+W)D9CI$
M97-C<FEP=&EO;CX*"B`\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TG=75I
M9#IA9F0W964U82UC,F-E+3$Q9&$M83<U8RTX-#ED.#$U86,S8V,G"B`@>&UL
M;G,Z<&AO=&]S:&]P/2=H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q
M+C`O)SX*("`\<&AO=&]S:&]P.DAI<W1O<GD^/"]P:&]T;W-H;W`Z2&ES=&]R
M>3X*(#PO<F1F.D1E<V-R:7!T:6]N/@H*(#QR9&8Z1&5S8W)I<'1I;VX@<F1F
M.F%B;W5T/2=U=6ED.F%F9#=E935A+6,R8V4M,3%D82UA-S5C+3@T.60X,35A
M8S-C8R<*("!X;6QN<SIT:69F/2=H='1P.B\O;G,N861O8F4N8V]M+W1I9F8O
M,2XP+R<^"B`@/'1I9F8Z3W)I96YT871I;VX^,3PO=&EF9CI/<FEE;G1A=&EO
M;CX*("`\=&EF9CI84F5S;VQU=&EO;CXW,B\Q/"]T:69F.EA297-O;'5T:6]N
M/@H@(#QT:69F.EE297-O;'5T:6]N/C<R+S$\+W1I9F8Z65)E<V]L=71I;VX^
M"B`@/'1I9F8Z4F5S;VQU=&EO;E5N:70^,CPO=&EF9CI297-O;'5T:6]N56YI
M=#X*(#PO<F1F.D1E<V-R:7!T:6]N/@H*(#QR9&8Z1&5S8W)I<'1I;VX@<F1F
M.F%B;W5T/2=U=6ED.F%F9#=E935A+6,R8V4M,3%D82UA-S5C+3@T.60X,35A
M8S-C8R<*("!X;6QN<SIX87`])VAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"\G/@H@(#QX87`Z0W)E871E1&%T93XR,#`V+3`T+3`S5#`Q.C`Q.C,U+3`U
M.C`P/"]X87`Z0W)E871E1&%T93X*("`\>&%P.DUO9&EF>41A=&4^,C`P-BTP
M-"TP,U0P,3HP,3HS-2TP-3HP,#PO>&%P.DUO9&EF>41A=&4^"B`@/'AA<#I-
M971A9&%T841A=&4^,C`P-BTP-"TP,U0P,3HP,3HS-2TP-3HP,#PO>&%P.DUE
M=&%D871A1&%T93X*("`\>&%P.D-R96%T;W)4;V]L/D%D;V)E(%!H;W1O<VAO
M<"!#4R!7:6YD;W=S/"]X87`Z0W)E871O<E1O;VP^"B`\+W)D9CI$97-C<FEP
M=&EO;CX*"B`\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TG=75I9#IA9F0W
M964U82UC,F-E+3$Q9&$M83<U8RTX-#ED.#$U86,S8V,G"B`@>&UL;G,Z>&%P
M34T])VAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\G/@H@(#QX87!-
M33I$;V-U;65N=$E$/F%D;V)E.F1O8VED.G!H;W1O<VAO<#IA9F0W964U.2UC
M,F-E+3$Q9&$M83<U8RTX-#ED.#$U86,S8V,\+WAA<$U-.D1O8W5M96YT240^
M"B`\+W)D9CI$97-C<FEP=&EO;CX*"B`\<F1F.D1E<V-R:7!T:6]N(')D9CIA
M8F]U=#TG=75I9#IA9F0W964U82UC,F-E+3$Q9&$M83<U8RTX-#ED.#$U86,S
M8V,G"B`@>&UL;G,Z9&,])VAT='`Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q
M+C$O)SX*("`\9&,Z9F]R;6%T/FEM86=E+VIP96<\+V1C.F9O<FUA=#X*(#PO
M<F1F.D1E<V-R:7!T:6]N/@H*/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"CP_
M>'!A8VME="!E;F0])W<G/S[_X@Q824-#7U!23T9)3$4``0$```Q(3&EN;P(0
M``!M;G1R4D="(%A96B`'S@`"``D`!@`Q``!A8W-P35-&5`````!)14,@<U)'
M0@``````````````````]M8``0````#3+4A0("``````````````````````
M`````````````````````````````````````````!%C<')T```!4````#-D
M97-C```!A````&QW='!T```!\````!1B:W!T```"!````!1R6%E:```"&```
M`!1G6%E:```"+````!1B6%E:```"0````!1D;6YD```"5````'!D;61D```"
MQ````(AV=65D```#3````(9V:65W```#U````"1L=6UI```#^````!1M96%S
M```$#````"1T96-H```$,`````QR5%)#```$/```"`QG5%)#```$/```"`QB
M5%)#```$/```"`QT97AT`````$-O<'ER:6=H="`H8RD@,3DY."!(97=L971T
M+5!A8VMA<F0@0V]M<&%N>0``9&5S8P`````````2<U)'0B!)14,V,3DV-BTR
M+C$``````````````!)S4D="($E%0S8Q.38V+3(N,0``````````````````
M````````````````````````````````````````````````6%E:(```````
M`/-1``$````!%LQ865H@`````````````````````%A96B````````!OH@``
M./4```.06%E:(````````&*9``"WA0``&-I865H@````````)*````^$``"V
MSV1E<V,`````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````````
M%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````````````````````````
M``````````````````````````````!D97-C`````````"Y)14,@-C$Y-C8M
M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M('-21T(`````````````
M`"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M('-2
M1T(`````````````````````````````9&5S8P`````````L4F5F97)E;F-E
M(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````````````
M+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$`
M`````````````````````````````````'9I97<``````!.D_@`47RX`$,\4
M``/MS``$$PL``UR>`````5A96B```````$P)5@!0````5Q_G;65A<P``````
M```!`````````````````````````H\````"<VEG(`````!#4E0@8W5R=@``
M``````0`````!0`*``\`%``9`!X`(P`H`"T`,@`W`#L`0`!%`$H`3P!4`%D`
M7@!C`&@`;0!R`'<`?`"!`(8`BP"0`)4`F@"?`*0`J0"N`+(`MP"\`,$`Q@#+
M`-``U0#;`.``Y0#K`/``]@#[`0$!!P$-`1,!&0$?`24!*P$R`3@!/@%%`4P!
M4@%9`6`!9P%N`74!?`&#`8L!D@&:`:$!J0&Q`;D!P0')`=$!V0'A`>D!\@'Z
M`@,"#`(4`AT")@(O`C@"00)+`E0"70)G`G$">@*$`HX"F`*B`JP"M@+!`LL"
MU0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#6@-F`W(#?@.*`Y8#H@.N`[H#QP/3
M`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q!'X$C`2:!*@$M@3$!-,$X03P!/X%
M#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&609J
M!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E!_@(
M"P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)N@G/
M">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X`+F`NP"\@+
MX0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-#0TF#4`-6@UT#8X-J0W##=X-^`X3
M#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[!`)$"800Q!A$'X0
MFQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3(Q-#
M$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/`5$A4T%585>!6;%;T5X!8#%B86
M219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$`891B*&*\8U1CZ&2`911EK
M&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H<`APJ'%(<>QRC',P<
M]1T>'4<=<!V9'<,=[!X6'D`>:AZ4'KX>Z1\3'SX?:1^4'[\?ZB`5($$@;""8
M(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_`D'R1-)'PD
MJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$HHBC4
M*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV*VDKG2O1+`4L.2QN+*(LURT,+4$M
M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C`U,&PPI##;,1(Q2C&",;HQ\C(J
M,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I-R0W
M8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\93RD
M/.,](CUA/:$]X#X@/F`^H#[@/R$_83^B/^)`(T!D0*9`YT$I06I!K$'N0C!"
M<D*U0O=#.D-]0\!$`T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(!4A+
M2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I-`DU*39--W$XE3FY.
MMT\`3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4VU4H
M5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N56^5<
M-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB\&-#
M8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(:I]J
M]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R2W*F
M<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&>J5[
M!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$>`J($*@6N!S8(P@I*"](-7
M@[J$'82`A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6B_R,
M8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4])5?
ME<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY`GJZ?
M'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H4JC$
MJ3>IJ:H<JH^K`JMUJ^FL7*S0K42MN*XMKJ&O%J^+L`"P=;#JL6"QUK)+LL*S
M.+.NM"6TG+43M8JV`;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[I[PAO)N]%;V/
MO@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&QL/'0<>_R#W(
MO,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1OM(_TL'31-/&
MU$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N`W`7<BMT0W9;>'-ZBWRG?
MK^`VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI1NG0ZEOJY>MP
MZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G]#3TPO50]=[V;?;[]XKX
M&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@`.061O8F4`9``````!
M_]L`A``&!`0$!00&!04&"08%!@D+"`8&"`L,"@H+"@H,$`P,#`P,#!`,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0<'!PT,#1@0$!@4#@X.%!0.#@X.
M%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_
MP``1"``U`+0#`1$``A$!`Q$!_]T`!``7_\0!H@````<!`0$!`0``````````
M!`4#`@8!``<("0H+`0`"`@,!`0$!`0`````````!``(#!`4&!P@)"@L0``(!
M`P,"!`(&!P,$`@8"<P$"`Q$$``4A$C%!408382)Q@10RD:$'%;%"(\%2T>$S
M%F+P)'*"\25#-%.2HK)C<\(U1">3H[,V%U1D=,/2X@@F@PD*&!F$E$5&I+16
MTU4H&O+C\\34Y/1E=865I;7%U>7U9G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<X
M2%AH>(B8J+C(V.CX*3E)66EYB9FIN<G9Z?DJ.DI::GJ*FJJZRMKJ^A$``@(!
M`@,%!00%!@0(`P-M`0`"$0,$(1(Q0051$V$B!G&!D3*AL?`4P='A(T(54F)R
M\3,D-$."%I)3):)CLL('<](UXD2#%U23"`D*&!DF-D4:)V1T53?RH[/#*"G3
MX_.$E*2TQ-3D]&5UA96EM<75Y?5&5F9VAI:FML;6YO9'5V=WAY>GM\?7Y_<X
M2%AH>(B8J+C(V.CX.4E9:7F)F:FYR=GI^2HZ2EIJ>HJ:JKK*VNKZ_]H`#`,!
M``(1`Q$`/P#U3BKL5=BKL5=BJ0^9O.VA>7C'!=.]QJ5QM::5:*9KN8_Y$2[T
M_P`M^*?Y6$1MHRZB,-C]7\V/U)1%;?F5KP]:YNX?*EB_]W:6Z)>7Q!_W[-)6
M")O\F..3_7P[!J`S3YGPA_IYJ?Y<:CY@EU;S/I>H:@VK6&CW<=M8ZC*B)*SF
M/G-&YC"HWI,56M,,D:6<S*42>*,3Z9?[IG.0<UV*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5__0]4XJA=1FO8;?U+2-)'4U<2,5`0`DFHKF'KLN;'CXL0C,
MCZN,\'H91`)W0FC>8(=1DDMV3TKJ+<I7DK+TY(U!49@=E=M0U4C`C@RP_AOB
MC./\_')E/'P[]$-J7F>XTYZ7.G.J,Q$<GJ*0U.^U:9B:_P!H,FE/[S#(1)/!
M+CCZ^%E#$)<BAQK.H:[:26VGQSV',B-]0A:%GBKU*B566M/\ELGV=V_/5GT8
M9<'%PSGQQ]'_`!3'-@VKBX2@;'2_+GDZ4Q:?`UYK5Y\5[J5W(9+B2O[4T[`M
M3_(7BG^3F1VKV['33&,#CRR\^"&./\Z<FG3:.,18_P!-_'),-7U77SIR6-C#
M&NOWY*6Q!+Q6\6W*ZE.WPQ@_"G^[).$>;'0SRSQ\641A+^@>+T_PL=1(CTP^
MJ7^Q_I)AY9\N6'EW1H-+LN3)'5Y9Y#62:5SRDED;]IY&/)LRR;7%B$(\(33`
MV.Q50O;ZULH#/<R".,;5.Y)\`!U.8VKUF+3PX\AX8LHQ)-!)T\[:*TG$^JJ_
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MT97D7)=BKL5?_]'U3BK3@E&`ZD$9&8L$*PBWF^J^8K2>5RB<']9WY#X55JDE
MI)30?ZV>>:0RAVEB.]S]/JXOZ4?X\N?_`'3ESK@*77_FL>9M._2%M:20:0MR
M8],NY1Q-V@3XYD0_$L7/X8R?M_:S8^VHK'C_`*TON#C:#-XED#T_P_TF1>0O
M]X+G_C+_`,:C)^QG]Q/_`(9_O0W:CF$OE,DWF34'!;DK",%>50!1:?#)$>V:
MK*93[0S2%V#P;<7]7^#+@_F_TF8V@&:K%&K,X4!V`#-W(7IOGHP<2EV*O(+K
M\^+RU\ZZGY<.A/>&SEFM[);1FDGN)HS2->'&BANKM\7!<L\/:W5'M(C(8<-T
MM\J_GGJ]SYTB\L^9]$&DS7,@@BHS\XY7%8UD5Q\0DJ`'7^;"<>UA&'M&1R<$
MX\+,O/PF_P!#._H_'\N6W\,\^]M1/]W_`#/5_I_2]!INJM::7H&K:,D-H$CN
MT1>3T_>*XZEN[`YD:7L[0Z[2"&+AAF$1ZO\`*QR?Q<?\Z/\`L6,IRC+?DG6B
M:4=,L_JWK&8<BP)%`*]0!OMG0=D]F_D\/A\7B;\7\UJR3XC:7V6O>OY@ET_Z
MLB<&D7U@?B/#Z.^:S2=L^)KI8.",>$S_`'G\7H9RQU&[8EJ7YMWVF?FC!Y-O
M--B2SN98HX=0$K<BLZ5C/`K3^\_=_:SJA#:W43UQCF\,C8_Q*GYJ?FU=>3-4
MTW3+'3DU&[OT:0H\ACXU<)&!16KS;E_P.,86G6:TX9"('$9*OYM?F!-Y/TC2
M[J72K?49KR1HY(9FHL;+'R/$\6KOMC"-IUNI\*()'%;)+;S19P>1H/,U[&+:
MU&GI?2PQ[A`8A)P3I7KQ7(UO3D1S`8A,\N'B>6:3^?/F368]0G;RK++H,*.E
MQ=67.:2W#*:&2H"/MNU.'%?BRPXP'68^TISL\'H_HI=_SBU_O?YA_P",-K_Q
M*7#E:^QN<O@RGSQ^><VE^9'\M>6=);6=4A?TIF^,KZH%6CCCC!>0I^V?AXY&
M,-K+E:CM'AGP0'')WD+\\KG6/,R^6O,>DG2=3E8QPLI<#U0.7IR1R`/&6`^$
MU;&6.A81INT3.?!,<,GK65NU?__2]4XJIW-S;VUO)<W$BPP0J9)97(55514L
MQ/0`8H)`%E@-K<IYBTY-=T*SN#:&:06KRI'%S56IS6,*&DAD_89FY?S+G%]L
M]CYL>09<$3.4)>)'@\./A_T?#CCA.?\`RLFV:;4QRQOI_2_B7>8-1N;BSM+>
M?3VL?0)"BA5"`H%$!`H!X9I.W^TLVHQPCEQ2PRB3]7%PS_J\0_XIR<.,1Y%?
MY<U:_L[.>&SL7NI)'J)%!*J>(&]!_')=A=IY\&&4,6*6:4I?5ZN"'I_BX1_O
MHIRP!.Y37R_H=T9&N;^)HY'?U'YF-N;5K]DHS(/]GFZ[%['RF1R9XF,I2\27
M'X<_$G_4\.4\?_*R+5DR#D&49V;CNQ5\Z>3O_6E-1_YBM0_Y-OETOI>?P?XX
M??+_`'S7YNJJ?GIH3H.+,VFLQ'<BY(K]PPP^E==_C,?\W_=/H/4(]/FMVAOB
MGHMU$A"[]B":;YK-=#!/&89N'@E_//"]%$D'9B&L^5[C3`;_`$^9C%%\1WI(
M@\01]H9PG:OL[/1CQ\$CP0W_`-MQ_P"=_$Y4,HEL60>5]7EU*P+3[SPMPD8;
M<MJALZCV=[4EJ\%S_O,9X)?TOYLFC-#A.R1:1_RFUQ_QDG_CG-]F?\;$_P"M
ME_2W3_NP\Z_YR3TV6QU;R_YIMA26)C`[`?MPMZ\-?^2F>DXST>8[6APRC,)<
M;F'SW^?UA+"1+IUDL$P[KPMH1.1_R/?CCRBUV,^J!_AC^/\`=)]_SE'_`,<+
M0_\`F*E_Y-8,3?VQ]$?>G7FPD?\`./`(-/\`</8C[_1&`?4W9O\`%/\`,C_O
M4%_SC^JC\K-28"A:ZN^1\:0H,.3FP[+_`+@^\_<QS_G%K_>[S#_QAM?^)2X<
MKC]C<Y?!D7F?SYY,\N>;9;+REY;BU?SI*[I-+;1A>,LGQ2*TB@O(_>4+_LY%
MR(B2-^3D9M3CQY*QQXLKSHS^9;C\]M(G\RVT-GK$E[9-/;6YJB*57TQ4,^_#
MCR^++-N'9U]S.J!F*E<7U-F.],__T_5.*O-=:DF_,'S1-Y:MG9?*.B2*?,$Z
M$CZW=*>2V:L/]UI]J?\`X'^7)C86Z_(3GGP#^[A]?]*7\QZ1##%#$D,*+'%&
MH2.-0`JJHH``.@`R#G@5LQ?S^0+2T8D!0[DD[``+U)SBO;,7CQ_UI.3I^J'_
M`"^O);FSF:UB+6;R\A>MM&X``_=#K)T^W_=_RL^9WLKHLN#!+Q!P2G+BX?X^
M'A_BC_!_G-.7,)GT[Q_G?P_YO\YF6=.Q=BKL5?+UM<^8+7\^M7N=`M([[4X;
MR^=+.5O3$J!6]1`W[+\*\/\`*R_;AW>:!F-43`<4KE^E,[#1?//GS\VK/7-5
MT2?2+.QF@><3(Z)'%:GF(P[JOJ/(X_9'[7\N)(`;8X\N?.)2CP"/^]>V^;-`
MEU!$N;4<KF$%2G3DG7:O<9QWM+V+/51&3'ODAZ>'^?#_`(J+T^')P[%)I;_S
M5<V7Z,>T<U`1Y/38.5'8L?A^G.?R:WM/-A_+''+^9*?!+CX?Z4OH_P`YM$8`
MW;(O+&CRZ98%9Z>O,W.11N%VH%KG6>SW9<M)@J?]Y,\4OZ/]%HRSXBE6F:??
M1^;I[E[>1;=GF*RE2%(-:;^^:3L_0YH]JSR&$AC,LOKX?1ZOZ39.0X*0GYS>
M6;CS#Y`OK6TA:XO[=H[JTAC')V>-J%5`ZEHV<9WD#1=3K\)R8B!S8/\`\X[^
M1-:T>^U?5M:T^:PG,<=K:)<1F-BK'G(RANWPQC)9)6X796FE`F4APIG_`,Y%
M^7M=UK1]'BTC3Y]0DAN9&E2WC:0JICH"W'IO@QFFWM7%*<1PCBW9-/Y7O=7_
M`"?B\NLA@OY=(@A$4HXE9XXE*J]?L_O%XM@OU6Y)PF6GX.O`'E7Y:7?YJZ%I
M]_Y/L_+$C/=2NPO+Q7AAMFD01NS-3A*E%#+P?_5YY9*CNZO1G/`'&(\_XI?P
MI]_SCKY6\Q:'?Z\=7TVYL4ECMU@>XC:,.4:2O'D-^HR.0@M_96&<#+B!BQ+R
M[9_F#Y`_,'4;E/+5QK4UR9H8Y5CD*2++*'$L<R*ZKRI\=?\`9<<D:(<7%'+@
MS$\)G:,7RW^95]^<.E>8-=T26+G=VDUQ);1L]O#$H4*ID'):QJ*2'E]K&QPT
MR\'-+4"<H]8OH_*'H7__U/3FKW)BM##%,D%[=AX+!I/L_6#&[I_Q`MA##(:'
MF?I2C\OO+8\L^3[#3IP$NTC];4I"P/*YE^.9F?\`:^,TY?RX9&RU:;%X>,`\
M_P"+^LE^K_FIH4-Z=*T&*3S)KAV%CIU'1#XS7']S$H_:);X?Y<1%A/61!X8_
MO)?T?^*05UY6\VZX(KOS,L%TZGG;:)`U+"`]C,6_>7LO^OQMO^*GS4]J'/0_
M+XXSR#Z<N3A_=?U(_P`]LQ83/?*=O]2C]'^?_/\`]RGN@VGF&P=DGMTDCFD5
MI)?4`*@`+L`.@`V7-/V1I^T-/(C)&.3Q9\>3)XGK_I?UG.R&!Y=&29UC0[%7
M8J\=\N?EIYLL?SHO/-=Q#$-&FGO)(Y!*I?C.C!/@Z]3EAD.&G4XM)..H,S]-
MR>Q96[9V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O_]7N7YP#RT?)Y&OF[$7U
MF'ZB=.%;L7>_I^B"0O*G/[1^SDH7;AZ[@\/U7S]/#]7$\P1?)ZF+_'$GG*2Q
MVX'64DCLZ?Y0@>1\LWZ4ZW]W_E/&K_;/H>T^3?\`!GZ'3_"7U/\`1G_+EQX\
MO\OC\7/_`(R?'E1OJ[?!X?#Z*K^BGN!O=BKL5=BKL5=BKL5=BKL5=BKL5=BK
1L5=BKL5=BKL5=BKL5=BK_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
